guest ::
| Home > Publications database > Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. > print |
| Home > Publications database > Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. > print |
| 001 | 136649 | ||
| 005 | 20240229105052.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.31352 |2 doi |
| 024 | 7 | _ | |a pmid:29492969 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6041155 |2 pmc |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:33971366 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-01118 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Abubakar, Mustapha |0 0000-0003-3728-6535 |b 0 |
| 245 | _ | _ | |a Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| 260 | _ | _ | |a Bognor Regis |c 2018 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1659440478_15546 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Chang-Claude, Jenny |0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |b 1 |
| 700 | 1 | _ | |a Ali, H Raza |b 2 |
| 700 | 1 | _ | |a Chatterjee, Nilanjan |b 3 |
| 700 | 1 | _ | |a Coulson, Penny |b 4 |
| 700 | 1 | _ | |a Daley, Frances |b 5 |
| 700 | 1 | _ | |a Blows, Fiona |b 6 |
| 700 | 1 | _ | |a Benitez, Javier |0 0000-0002-0923-7202 |b 7 |
| 700 | 1 | _ | |a Milne, Roger L |b 8 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 9 |
| 700 | 1 | _ | |a Stegmaier, Christa |b 10 |
| 700 | 1 | _ | |a Mannermaa, Arto |b 11 |
| 700 | 1 | _ | |a Rudolph, Anja |0 P:(DE-He78)3c7f9136fb168ffb766316ea4ca1a58b |b 12 |u dkfz |
| 700 | 1 | _ | |a Sinn, Peter |b 13 |
| 700 | 1 | _ | |a Couch, Fergus J |b 14 |
| 700 | 1 | _ | |a Devilee, Peter |b 15 |
| 700 | 1 | _ | |a Tollenaar, Rob A E M |b 16 |
| 700 | 1 | _ | |a Seynaeve, Caroline |b 17 |
| 700 | 1 | _ | |a Figueroa, Jonine |b 18 |
| 700 | 1 | _ | |a Lissowska, Jolanta |b 19 |
| 700 | 1 | _ | |a Hewitt, Stephen |b 20 |
| 700 | 1 | _ | |a Hooning, Maartje J |b 21 |
| 700 | 1 | _ | |a Hollestelle, Antoinette |b 22 |
| 700 | 1 | _ | |a Foekens, Renée |b 23 |
| 700 | 1 | _ | |a Koppert, Linetta B |b 24 |
| 700 | 1 | _ | |a Investigators, kConFab |b 25 |
| 700 | 1 | _ | |a Bolla, Manjeet K |b 26 |
| 700 | 1 | _ | |a Wang, Qin |b 27 |
| 700 | 1 | _ | |a Jones, Michael E |b 28 |
| 700 | 1 | _ | |a Schoemaker, Minouk J |b 29 |
| 700 | 1 | _ | |a Keeman, Renske |b 30 |
| 700 | 1 | _ | |a Easton, Douglas F |b 31 |
| 700 | 1 | _ | |a Swerdlow, Anthony J |b 32 |
| 700 | 1 | _ | |a Sherman, Mark E |b 33 |
| 700 | 1 | _ | |a Schmidt, Marjanka K |b 34 |
| 700 | 1 | _ | |a Pharoah, Paul D |b 35 |
| 700 | 1 | _ | |a Garcia-Closas, Montserrat |b 36 |
| 773 | _ | _ | |a 10.1002/ijc.31352 |g Vol. 143, no. 4, p. 746 - 757 |0 PERI:(DE-600)1474822-8 |n 4 |p 746 - 757 |t International journal of cancer |v 143 |y 2018 |x 0020-7136 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:136649 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)3c7f9136fb168ffb766316ea4ca1a58b |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Cancer risk factors and prevention |x 0 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G110-20160331 |k G110 |l Präventive Onkologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G110-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|